Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NEPH 
Nephros Inc (NEPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: NEPH (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 95.03% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.72M USD | Price to earnings Ratio 31.08 | 1Y Target Price 5.5 |
Price to earnings Ratio 31.08 | 1Y Target Price 5.5 | ||
Volume (30-day avg) 2 | Beta 1.11 | 52 Weeks Range 1.36 - 5.00 | Updated Date 08/29/2025 |
52 Weeks Range 1.36 - 5.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.01 | Actual 0.02 |
Profitability
Profit Margin 7.95% | Operating Margin (TTM) 5.61% |
Management Effectiveness
Return on Assets (TTM) 7.16% | Return on Equity (TTM) 15.14% |
Valuation
Trailing PE 31.08 | Forward PE - | Enterprise Value 38887434 | Price to Sales(TTM) 2.56 |
Enterprise Value 38887434 | Price to Sales(TTM) 2.56 | ||
Enterprise Value to Revenue 2.33 | Enterprise Value to EBITDA 26.03 | Shares Outstanding 10600600 | Shares Floating 9243833 |
Shares Outstanding 10600600 | Shares Floating 9243833 | ||
Percent Insiders 11.19 | Percent Institutions 45.78 |
Upturn AI SWOT
Nephros Inc
Company Overview
History and Background
Nephros, Inc. was founded to develop and commercialize medical devices and technologies for patients with critical medical needs, focusing on kidney care and pathogen reduction.
Core Business Areas
- Water Purification and Pathogen Reduction: Development and sale of ultrafilters and related devices for hemodialysis, sterile water supply, and infection control.
- Renal Products: Development and distribution of hemodialysis products.
Leadership and Structure
Specifics on the leadership team and organizational structure are available on their corporate website and SEC filings, including information on the CEO, CFO, and board members. Organizational structure information requires detailed research of public filings and company information.
Top Products and Market Share
Key Offerings
- Hemodialysis Ultrafilters: Nephros ultrafilters are used in hemodialysis to remove toxins and excess fluid from patients with kidney failure. Market share data is not readily available and requires specialized industry reports. Competitors include Fresenius Medical Care (FMS) and Baxter International (BAX).
- AAMI-Quality Water Systems: Systems that produce water meeting stringent AAMI standards for dialysis water. Market share data is not readily available and requires specialized industry reports. Competitors include Mar Cor Purification and Evoqua Water Technologies (AQUA).
Market Dynamics
Industry Overview
The dialysis and pathogen reduction markets are driven by the increasing prevalence of kidney disease, growing awareness of infection control, and technological advancements in treatment methods.
Positioning
Nephros positions itself as an innovator in water purification and pathogen reduction technologies, offering specialized products for niche applications within the dialysis and healthcare markets.
Total Addressable Market (TAM)
TAM for dialysis and pathogen reduction estimated at $15B globally. Nephros is positioned in specific segments of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary ultrafiltration technology
- Focus on niche applications
- Established presence in dialysis centers
Weaknesses
- Limited financial resources
- Small market share compared to industry giants
- Dependence on key customers
Opportunities
- Expanding into new geographic markets
- Developing new applications for ultrafiltration technology
- Partnering with larger medical device companies
Threats
- Competition from established players
- Changes in healthcare regulations
- Technological obsolescence
Competitors and Market Share
Key Competitors
- FMS
- BAX
- AQUA
Competitive Landscape
Nephros faces significant competition from larger, more established companies with greater resources and broader product portfolios. Nephros' advantage lies in its niche products and specialized technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on sales of hemodialysis filters and water purification products. Requires financial analysis not populated here due to dynamic nature.
Future Projections: Future growth projections require analyzing analyst reports and company guidance, not populated here due to dynamic nature.
Recent Initiatives: Recent initiatives require review of press releases and investor presentations, not populated here due to dynamic nature.
Summary
Nephros Inc. is a small player in a competitive market. It focuses on niche areas such as water purification and pathogen reduction. They are growing but face competition from companies with more resources. They need to capitalize on their opportunities and mitigate against external threats and risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports (requiring subscription)
- Analyst reports (requiring subscription)
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share estimates are approximate and may vary depending on the source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nephros Inc
Exchange NASDAQ | Headquaters South Orange, NJ, United States | ||
IPO Launch date 2004-09-21 | President, CEO & Director Mr. Robert Banks | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 31 | Website https://www.nephros.com |
Full time employees 31 | Website https://www.nephros.com | ||
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, bacteria, cysts, particulates, heavy metals, chemical compounds, scale build-up in downstream equipment, and other various contaminants. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.